Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
M3, Inc. (2413.T)
Tokyo, JP
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.15% | -0.89% | -16.51% | -22.07% | -37.31% | -35.59% | -30.20% | -56.17% | -81.50% | -16.30% | +1,334.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+23.3% ★ Q1'26: +9.6% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+21.6% Q1'26: -5.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+15.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+20.0% ★ Q1'26: +17.3% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+15.4% ★ Q1'26: +13.7% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%-0.3% ★ Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.38× ★ Q1'26: 0.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 13 EPS Ana. |
Mar 2027 11 Rev. Ana. 13 EPS Ana. |
Mar 2028 13 Rev. Ana. 13 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
Mar 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
51.35B
est: 52.43B (-2.1%)
|
64.66B
est: 64.03B (+1.0%)
|
78.14B
est: 76.93B (+1.6%)
|
94.47B
est: 94.54B (-0.1%)
|
113.06B
est: 113.91B (-0.7%)
|
130.97B
est: 131.37B (-0.3%)
|
169.20B
est: 168.67B (+0.3%)
|
208.16B
est: 206.70B (+0.7%)
|
230.82B
est: 233.04B (-1.0%)
|
238.88B
est: 245.70B (-2.8%)
|
284.90B
est: 281.17B (+1.3%)
|
354.65B
350.77B – 360.25B
+26.1% YoY
|
392.52B
385.73B – 409.23B
+10.7% YoY
|
429.66B
414.24B – 463.30B
+9.5% YoY
|
462.29B
462.29B – 462.29B
+7.6% YoY
|
516.74B
502.77B – 548.39B
+11.8% YoY
|
612.30B
595.75B – 649.81B
+18.5% YoY
|
| EBITDA |
16.85B
est: 19.02B (-11.4%)
|
20.97B
est: 23.23B (-9.7%)
|
26.00B
est: 27.91B (-6.8%)
|
30.91B
est: 34.30B (-9.9%)
|
32.34B
est: 41.32B (-21.7%)
|
39.14B
est: 47.66B (-17.9%)
|
64.11B
est: 61.19B (+4.8%)
|
102.51B
est: 74.99B (+36.7%)
|
81.82B
est: 84.54B (-3.2%)
|
78.11B
est: 83.30B (-6.2%)
|
77.71B
est: 95.33B (-18.5%)
|
120.24B
118.93B – 122.14B
+26.1% YoY
|
133.08B
130.78B – 138.75B
+10.7% YoY
|
145.67B
140.45B – 157.08B
+9.5% YoY
|
156.74B
156.74B – 156.74B
+7.6% YoY
|
175.20B
170.46B – 185.93B
+11.8% YoY
|
207.60B
201.99B – 220.32B
+18.5% YoY
|
| EBIT |
16.18B
est: 17.17B (-5.8%)
|
20.10B
est: 20.97B (-4.2%)
|
25.06B
est: 25.20B (-0.5%)
|
29.75B
est: 30.97B (-3.9%)
|
30.95B
est: 37.31B (-17.0%)
|
34.65B
est: 43.03B (-19.5%)
|
58.38B
est: 55.25B (+5.7%)
|
96.24B
est: 67.70B (+42.1%)
|
74.39B
est: 76.33B (-2.5%)
|
69.23B
est: 73.90B (-6.3%)
|
65.50B
est: 84.57B (-22.5%)
|
106.67B
105.50B – 108.35B
+26.1% YoY
|
118.06B
116.02B – 123.09B
+10.7% YoY
|
129.23B
124.59B – 139.35B
+9.5% YoY
|
139.04B
139.04B – 139.04B
+7.6% YoY
|
155.42B
151.22B – 164.94B
+11.8% YoY
|
184.16B
179.18B – 195.44B
+18.5% YoY
|
| Net Income |
9.76B
est: 10.63B (-8.2%)
|
12.51B
est: 13.11B (-4.6%)
|
16.00B
est: 16.38B (-2.3%)
|
19.68B
est: 20.96B (-6.1%)
|
19.58B
est: 21.74B (-10.0%)
|
21.64B
est: 23.47B (-7.8%)
|
37.82B
est: 37.82B (+0.0%)
|
63.85B
est: 67.26B (-5.1%)
|
49.03B
est: 51.06B (-4.0%)
|
45.27B
est: 44.11B (+2.6%)
|
40.48B
est: 44.39B (-8.8%)
|
49.10B
48.78B – 53.61B
+10.6% YoY
|
54.63B
52.97B – 58.42B
+11.3% YoY
|
61.98B
58.60B – 67.95B
+13.4% YoY
|
69.03B
64.41B – 77.65B
+11.4% YoY
|
80.18B
77.36B – 86.57B
+16.2% YoY
|
104.29B
100.62B – 112.59B
+30.1% YoY
|
| SGA |
15.23B
est: 14.18B (+7.4%)
|
17.84B
est: 17.32B (+3.0%)
|
21.67B
est: 20.81B (+4.1%)
|
26.32B
est: 25.57B (+2.9%)
|
35.10B
est: 30.81B (+13.9%)
|
35.57B
est: 35.53B (+0.1%)
|
40.91B
est: 45.62B (-10.3%)
|
51.14B
est: 55.91B (-8.5%)
|
58.99B
est: 63.03B (-6.4%)
|
67.65B
est: 67.54B (+0.2%)
|
82.37B
est: 77.29B (+6.6%)
|
97.49B
96.43B – 99.03B
+26.1% YoY
|
107.90B
106.04B – 112.50B
+10.7% YoY
|
118.11B
113.87B – 127.36B
+9.5% YoY
|
127.08B
127.08B – 127.08B
+7.6% YoY
|
142.05B
138.21B – 150.75B
+11.8% YoY
|
168.32B
163.77B – 178.63B
+18.5% YoY
|
| EPS |
15.09
est: 15.65 (-3.6%)
|
19.33
est: 19.30 (+0.1%)
|
24.72
est: 24.11 (+2.5%)
|
30.39
est: 30.86 (-1.5%)
|
30.22
est: 32.01 (-5.6%)
|
31.89
est: 34.56 (-7.7%)
|
55.73
est: 55.68 (+0.1%)
|
94.06
est: 99.02 (-5.0%)
|
72.22
est: 75.17 (-3.9%)
|
66.68
est: 64.96 (+2.7%)
|
59.62
est: 64.12 (-7.0%)
|
75.27
72.03 – 79.16
+17.4% YoY
|
82.93
78.23 – 86.27
+10.2% YoY
|
93.68
86.53 – 100.33
+13.0% YoY
|
105.12
95.11 – 114.66
+12.2% YoY
|
118.40
114.24 – 127.83
+12.6% YoY
|
154.00
148.59 – 166.27
+30.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Itaru Tanimura | President & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2413.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
